Ji, M. F. et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann. Oncol. 30, 1630–1637 (2019).
Article CAS PubMed Google Scholar
Chan, K. C. A. et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513–522 (2017).
Article CAS PubMed Google Scholar
Li, T. et al. Anti-Epstein-Barr virus BNLF2b for mass screening for nasopharyngeal cancer. N. Engl. J. Med. 389, 808–819 (2023).
Article CAS PubMed Google Scholar
Coghill, A. E. et al. Identification of a novel, EBV-based antibody risk stratification signature for early detection of nasopharyngeal carcinoma in Taiwan. Clin. Cancer Res. 24, 1305–1314 (2018).
Article CAS PubMed PubMed Central Google Scholar
Lou, P. J. et al. Performance and operational feasibility of Epstein-Barr virus-based screening for detection of nasopharyngeal carcinoma: direct comparison of two alternative approaches. J. Clin. Oncol. 41, 4257–4266 (2023).
Article CAS PubMed Google Scholar
Lam, W. K. J. et al. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc. Natl Acad. Sci. USA 115, E5115–E5124 (2018).
Article CAS PubMed PubMed Central Google Scholar
Chan, K. C. A. et al. Plasma Epstein-Barr virus DNA and risk of future nasopharyngeal cancer. NEJM Evid. 2, https://doi.org/10.1056/EVIDoa2200309 (2023).
Miller, J. A., Le, Q. T., Pinsky, B. A. & Wang, H. Cost-effectiveness of nasopharyngeal carcinoma screening with Epstein-Barr virus polymerase chain reaction or serology in high-incidence populations worldwide. J. Natl. Cancer Inst. 113, 852–862 (2021).
Lam, W. K. J. et al. Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions. J. Natl. Cancer Inst. 115, 355–364 (2023).
Comments (0)